141 related articles for article (PubMed ID: 21910763)
1. Sorafenib before liver transplantation for hepatocellular carcinoma: risk or give up.
Di Benedetto F; Tarantino G; Montalti R; Ballarin R; D'Amico G; Berretta M; Gerunda GE
Transpl Int; 2011 Nov; 24(11):e97; author reply e98-9. PubMed ID: 21910763
[No Abstract] [Full Text] [Related]
2. [Hepatocellular carcinoma management in the era of sorafenib].
Rosmorduc O
Gastroenterol Clin Biol; 2009 Apr; 33(4):327-33. PubMed ID: 19321281
[No Abstract] [Full Text] [Related]
3. Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Diaz-Sanchez A; Rodriguez-Salas N; Aramendi T; Balbin E
Dig Liver Dis; 2011 Apr; 43(4):333-4. PubMed ID: 21215716
[No Abstract] [Full Text] [Related]
4. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
Truesdale AE; Caldwell SH; Shah NL; Argo CK; Al-Osaimi AM; Schmitt TM; Northup PG
Transpl Int; 2011 Oct; 24(10):991-8. PubMed ID: 21777298
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
[No Abstract] [Full Text] [Related]
6. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
7. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
8. Sorafenib-induced hepatic encephalopathy.
Marks AB; Gerard R; Fournier P; Coupe P; Gautier S
Ann Pharmacother; 2009 Dec; 43(12):2121. PubMed ID: 19861429
[No Abstract] [Full Text] [Related]
9. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
11. Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Schütte K; Zimmermann L; Bornschein J; Csepregi A; Rühl R; Ricke J; Malfertheiner P
Digestion; 2011; 83(4):275-82. PubMed ID: 21282952
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
[TBL] [Abstract][Full Text] [Related]
13. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Boige V; Barbare JC; Rosmorduc O;
Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
[No Abstract] [Full Text] [Related]
14. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
[TBL] [Abstract][Full Text] [Related]
15. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
16. Closing remarks.
Kudo M
Clin Drug Investig; 2012 Aug; 32 Suppl 2():52. PubMed ID: 22873627
[No Abstract] [Full Text] [Related]
17. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Mancuso A; Airoldi A; Vigano R; Pinzello G
Dig Liver Dis; 2011 Sep; 43(9):754. PubMed ID: 21641889
[No Abstract] [Full Text] [Related]
18. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
19. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]